Macular Edema

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

6100%

+ 43 programs with unclassified modality

On Market (2)

Approved therapies currently available

OZURDEXApproved

dexamethasone

AbbVie

Corticosteroid [EPC]intravitreal2009

2M Part D

AEROSEB-DEXApproved

dexamethasone

AbbVie

topical

Competitive Landscape

20 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AbbVieNORTH CHICAGO, IL

19 programs

OZURDEXPhase 41 trial

Ozurdex Intravitreal InjectionPhase 41 trial

dexamethasone implantPhase 41 trial

700 µg DexamethasonePhase 31 trial

+14 more programs

Active Trials

NCT01805323Completed101Est. Apr 2013

NCT01945892Completed23Est. Jul 2013

NCT01571557Completed573Est. Jun 2014

+16 more trials

SandozAustria - Kundl

5 programs

Ranibizumab 0.5 mg/0.05 mlPhase 31 trial

Ranibizumab 0.5mgPhase 31 trial

ranibizumabPhase 3Monoclonal Antibody1 trial

LKA651Phase 11 trial

MHU650Phase 11 trial

Active Trials

NCT02867735Completed28Est. Feb 2018

NCT04635800Completed21Est. May 2022

NCT01535261Completed357Est. Mar 2015

+2 more trials

Clearside BiomedicalGA - Alpharetta

3 programs

suprachoroidal CLS-TAPhase 31 trial

4 mg CLS-TAPhase 21 trial

Active Trials

NCT02303184Completed46Est. Mar 2016

NCT02980874Terminated460Est. Dec 2018

NCT03203447Terminated325Est. Dec 2018

Kodiak SciencesCA - Palo Alto

1 program

KSI-301Phase 31 trial

Active Trials

NCT04592419Completed568Est. Jan 2023

BayerLEVERKUSEN, Germany

1 program

VEGF Trap-EyePhase 31 trial

Active Trials

NCT01512966Completed73Est. Sep 2013

PfizerNEW YORK, NY

1 program

pegaptanib sodiumPhase 31 trial

Active Trials

NCT01100307Completed243Est. Aug 2012

AlconFORT WORTH, TX

1 program

Nepafenac ophthalmic suspension, 0.1%Phase 21 trial

Active Trials

NCT00782717Completed263Est. Jul 2010

MSDIreland - Ballydine

1 program

triamcinolone acetonidePhase 2

Sharp TherapeuticsPA - Pittsburgh

1 program

triamcinolone acetonidePhase 21 trial

Active Trials

NCT00692614Terminated2Est. Nov 2008

ViiV HealthcareNC - Durham

1 program

GSK2798745Phase 1

Kubota VisionJapan - Tokyo

2 programs

RHMS-RTMN/A1 trial

Active Trials

NCT04428242Withdrawn0Est. Jul 2020

NCT04499703Completed60Est. Jan 2021

NovartisBASEL, Switzerland

2 programs

LKA651PHASE_1

MHU650PHASE_1

GenentechCA - Oceanside

2 programs

Intravitreal injection of ranibizumab .3 dosePHASE_1_21 trial

RanibizumabPHASE_4Monoclonal Antibody1 trial

Active Trials

NCT00407355Completed40Est. Feb 2013

NCT01277302Completed202Est. Oct 2012

Boehringer IngelheimINGELHEIM, Germany

2 programs

BI 1026706PHASE_21 trial

BI 1815368PHASE_21 trial

Active Trials

NCT02732951Completed105Est. Oct 2017

NCT06962839Recruiting300Est. Mar 2028

Chugai PharmaJapan - Tokyo

2 programs

FaricimabPHASE_3Monoclonal Antibody

Coordination PharmaceuticalsIL - Chicago

1 program

RanibizumabN/AMonoclonal Antibody1 trial

Active Trials

NCT00562406Completed30Est. Sep 2010

GSKLONDON, United Kingdom

1 program

GSK2798745PHASE_11 trial

Active Trials

NCT04292912Terminated16Est. Apr 2022

Merck & Co.RAHWAY, NJ

1 program

triamcinolone acetonidePHASE_2

RegeneronTARRYTOWN, NY

1 program

AfliberceptPHASE_3

RocheSTAVANGER NORWAY, Norway

1 program

FaricimabPHASE_3Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

AbbVieOZURDEX

AbbViedexamethasone implant

AbbVieOzurdex Intravitreal Injection

GenentechRanibizumab

AbbVieUpdated DEX PS DDS Applicator

Kodiak SciencesKSI-301

Clearside Biomedicalsuprachoroidal CLS-TA

AbbVieDexamethasone

SandozRanibizumab 0.5mg

AbbVie700 μg Dexamethasone

SandozRanibizumab 0.5 mg/0.05 ml

BayerVEGF Trap-Eye

Pfizerpegaptanib sodium

Sandozranibizumab

Showing 15 of 40 trials with date data

Clinical Trials (40)

Total enrollment: 7,348 patients across 40 trials

NCT03908307 AbbVieOZURDEX

Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Start: Jul 2019Est. completion: Sep 2021150 patients

Phase 4Completed

NCT01903720 AbbViedexamethasone implant

A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion

Start: Jul 2013Est. completion: Mar 201571 patients

Phase 4Completed

NCT01870440 AbbVieOzurdex Intravitreal Injection

TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema

Start: May 2013Est. completion: Feb 201510 patients

Phase 4Completed

NCT01277302 GenentechRanibizumab

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

Start: Feb 2011Est. completion: Oct 2012202 patients

Phase 4Completed

NCT04976777 AbbVieUpdated DEX PS DDS Applicator

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

Start: Oct 2021Est. completion: Feb 202254 patients

Phase 3Completed

NCT04592419 Kodiak SciencesKSI-301

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Start: Sep 2020Est. completion: Jan 2023568 patients

Phase 3Completed

NCT03203447 Clearside Biomedicalsuprachoroidal CLS-TA

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Start: Mar 2018Est. completion: Dec 2018325 patients

Phase 3Terminated

NCT02980874 Clearside Biomedicalsuprachoroidal CLS-TA

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Start: Jan 2017Est. completion: Dec 2018460 patients

Phase 3Terminated

NCT02121262 AbbVieDexamethasone

A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema

Start: Jan 2016Est. completion: Nov 2019284 patients

Phase 3Completed

NCT02032173 SandozRanibizumab 0.5mg

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

Start: May 2014Est. completion: Apr 201531 patients

Phase 3Terminated

NCT01660802 AbbVie700 μg Dexamethasone

Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)

Start: Sep 2012Est. completion: May 2014262 patients

Phase 3Completed

NCT01535261 SandozRanibizumab 0.5 mg/0.05 ml

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Start: Feb 2012Est. completion: Mar 2015357 patients

Phase 3Completed

NCT01512966 BayerVEGF Trap-Eye

Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)

Start: Jan 2012Est. completion: Sep 201373 patients

Phase 3Completed

NCT01100307 Pfizerpegaptanib sodium

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

Start: May 2010Est. completion: Aug 2012243 patients

Phase 3Completed

NCT00942864 Sandozranibizumab

Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

Start: Dec 2008Est. completion: Dec 200940 patients

Phase 3Completed

NCT00168298 AbbVie700 µg Dexamethasone

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Start: Nov 2004Est. completion: Sep 2008668 patients

Phase 3Completed

NCT00168324 AbbVie700 µg Dexamethasone

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Start: Oct 2004Est. completion: Oct 2008599 patients

Phase 3Completed

NCT06962839 Boehringer IngelheimBI 1815368

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Start: Jun 2025Est. completion: Mar 2028300 patients

Phase 2Recruiting

NCT02732951 Boehringer IngelheimBI 1026706

Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema

Start: Apr 2016Est. completion: Oct 2017105 patients

Phase 2Completed

NCT02303184 Clearside Biomedical4 mg CLS-TA

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Start: Jan 2015Est. completion: Mar 201646 patients

Phase 2Completed

NCT02186119 AbbVieabicipar pegol

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

Start: Jul 2014Est. completion: Jun 2015151 patients

Phase 2Completed

NCT01471054 AbbVieOzurdex

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Start: Apr 2014Est. completion: Jul 20156 patients

Phase 2Terminated

NCT01673191 AbbVieDexamethasone intravitreal implant

A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

Start: Nov 2012Est. completion: Dec 201440 patients

Phase 2Completed

NCT01492400 AbbViedexamethasone Intravitreal Implant

Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

Start: Mar 2012Est. completion: Feb 2014363 patients

Phase 2Completed

NCT00782717 AlconNepafenac ophthalmic suspension, 0.1%

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

Start: Nov 2008Est. completion: Jul 2010263 patients

Phase 2Completed

NCT00692614 Sharp Therapeuticstriamcinolone acetonide

A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)

Start: Jun 2008Est. completion: Nov 20082 patients

Phase 2Terminated

NCT01027650 AbbVieAGN208397 intravitreal injection

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

Start: Mar 2010Est. completion: Feb 2013121 patients

Phase 1/2Completed

NCT00407355 GenentechIntravitreal injection of ranibizumab .3 dose

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

Start: Jan 2006Est. completion: Feb 201340 patients

Phase 1/2Completed

NCT04635800 SandozMHU650

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Start: Dec 2020Est. completion: May 202221 patients

Phase 1Completed

NCT04292912 GSKGSK2798745

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

Start: Sep 2020Est. completion: Apr 202216 patients

Phase 1Terminated

NCT02867735 SandozLKA651

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Start: Sep 2016Est. completion: Feb 201828 patients

Phase 1Completed

NCT04499703 Kubota VisionRHMS-RTM

Evaluation of the Retinal Health Monitoring System Thickness Module

Start: Nov 2020Est. completion: Jan 202160 patients

N/ACompleted

NCT04428242 Kubota VisionRHMS-RTM

Study Evaluating Retinal Health Monitoring System Thickness Module

Start: Apr 2020Est. completion: Jul 20200

N/AWithdrawn

NCT02188173 AbbViedexamethasone 700 ㎍ intravitreal implant

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

Start: Jul 2014Est. completion: May 2016200 patients

N/ACompleted

NCT01805323 AbbVieDexamethasone Intravitreal Implant

A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema

Start: Sep 2012Est. completion: Apr 2013101 patients

N/ACompleted

NCT01571557 AbbViedexamethasone 700 ug intravitreal implant

A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)

Start: Apr 2012Est. completion: Jun 2014573 patients

N/ACompleted

NCT01945892 AbbVieOzurdex

Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome

Start: Nov 2011Est. completion: Jul 201323 patients

N/ACompleted

NCT01618266 AbbViedexamethasone intravitreal implant

Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion

Start: Nov 2011Est. completion: Oct 2014375 patients

N/ACompleted

NCT01445626 AbbViedexamethasone intravitreal implant 0.7 mg

A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

Start: Oct 2011Est. completion: Jan 201287 patients

N/ACompleted

NCT00562406 Coordination PharmaceuticalsRanibizumab

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

Start: Nov 2007Est. completion: Sep 201030 patients

N/ACompleted

Related Jobs

Associate Director, US Marketing Ophthalmology, Patient Experience Measurement & Engagement

Merck & Co.

USA - Pennsylvania - North Wales (Upper Gwynedd); USA - New Jersey - Rahway (Hybrid)

2d ago

$142K - $224K/yr

Associate Director, US Marketing Ophthalmology, Patient Support Program Access and Affordability Lead

Merck & Co.

USA - Pennsylvania - North Wales (Upper Gwynedd); USA - New Jersey - Rahway (Hybrid)

2d ago

$142K - $224K/yr

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

13 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 7,348 patients

20 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.